1. Public Law 98-417. Drug price competition and patent term restoration act of 1984. 98 Stat, 24 September; 1984. p. 1585–1605.
2. US-FDA. Orange book: approved drug products with therapeutic equivalence evaluations. 2016.
http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm. Accessed 11 Apr. 2016
.
3. US Government Printing Office. Electronic code of federal regulations. Title 21. Chapter I. Subchapter D. Part 320. Bioavailability and bioequivalence requirements. 2016.
http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=86c1665448bdfc4a2adaa0cd8a2afad5&mc=true&n=pt21.5.320&r=PART&ty=HTML
. Accessed 11 Apr 2016.
4. Pfizer Inc. v Shalala (1999) 182 F.3d 975.
5. Davit BM, Braddy AC, Conner DP, Yu LX. International guidelines for bioequivalence of systemically available generic drug products: a survey of similarities and differences. AAPS J. 2013;15:974–90.
https://doi.org/10.1208/s12248-013-9499-x
.